Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Retatrutide in Obesity or Overweight (TRIUMPH-1)
NCT05929066Phase 3Completed
- Sponsor
- Eli Lilly and Company
- Start
- Jul 2023
- Primary completion
- Apr 2026
- Modality
- Peptides, Small Molecules
- Countries
- 12
01
Overview
A Phase 3 trial of retatrutide in obesity, Overweight, osteoarthritis (OA), obstructive sleep apnea (OSA), sponsored by Eli Lilly and Company. Started Jul 2023; status: completed.
02
Drugs
03
Conditions
obesityOverweightosteoarthritis (OA)obstructive sleep apnea (OSA)
Beyond the preview
Go deeper on NCT05929066.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05929066.